Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.

Blood - 1 Nov 2006

Ishii Takefumi, Bruno Edward, Hoffman Ronald, Xu Mingjiang

Abstract excerpt

The JAK2(V617F) mutation has been shown to occur in the overwhelming majority of patients with polycythemia vera (PV). To study the role of the mutation in the excessive production of differentiated hematopoietic cells in PV, CD19+, CD3+, CD34+, CD33+, and glycophorin A+ cells and granulocytes we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to Antigens, CD
Share to Glycophorins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Granulocytes

Share to Hematopoietic Stem Cells

Share to Janus Kinase 2

Share to Polycythemia Vera

Share to Reference Values

Source

Identifiers

PMID: 16757685
DOI: 10.1182/blood-2006-04-017392

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16757685-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.PMID 16757685Read ↗

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.Semantic proximity Read ↗

The <i>JAK2</i> V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiationSemantic proximity Read ↗

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.Semantic proximity Read ↗

Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.Semantic proximity Read ↗

[Myeloproliferative diseases caused by JAK2 mutation].Semantic proximity Read ↗

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.Semantic proximity Read ↗

The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?Semantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.Semantic proximity Read ↗

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden.Semantic proximity Read ↗

Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.Semantic proximity Read ↗

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.